DTx Pharma to Present at the Virtual 7th Solebury Trout Fall Private Company Showcase
PR Newswire, San Diego – October 5, 2020 – DDTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the [...]
DTx Pharma to Present at the Chardan Virtual 4th Annual Genetic Medicines Event
PR Newswire, San Diego – September 28, 2020 – DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the [...]
DTx Pharma Receives New Funding Grant to Advance RNA-based Therapeutic Programs for Charcot-Marie Tooth (CMT)
-CMT is a genetic rare disease driven by the duplication of the PMP22 gene- PR Newswire, San Diego – September 21, 2020 – DTx Pharma, [...]
DTx Pharma Announces Presentations at Several Upcoming Virtual Medical Meetings
DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, announced today that the company will [...]
DTx Pharma Announces Appointment of Bryan Laffitte, Ph.D. as Vice President, Biology
DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, announced today the appointment of [...]
DTx Pharma Expands Footprint in San Diego with New Office and Lab Space
SAN DIEGO, May 20, 2020 /PRNewswire/ -- DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers [...]
DTx Pharma Receives Prestigious Funding Award to Support Research in Neurodegenerative Diseases of the CNS
-DTx was one of 8 grantees selected out of more than 100 academic and company applicants worldwide- SAN DIEGO, May 13, 2020 /PRNewswire/ -- DTx [...]
DTx Pharma Completes $10.6M Series A Financing
DTx Pharma announced today the final closing of a Series A financing totaling $10.6 million dollars. The round was led by San Diego-based FBV [...]
Partnership with DTx Pharma to optimize antisense oligonucleotides as a gene therapy for CMT1A
The CMT Research Foundation (CMTRF), a nonprofit focused solely on delivering treatments and cures for Charcot-Marie-Tooth, today announced it has partnered with DTx Pharma, an RNA medicines company [...]
DTx receives 3rd NIH SBIR in 2019: Targeting Tau in Neurodegenerative Disease
DTx received a notice of award in September for our first CNS focused grant, targeting the Tau gene/protein implicated in FTLD’s such as PSP as [...]